Study to Assess the Effect of Meplazumab on COVID-19
Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
This phase2/3 study will be conducted to evaluate the safety and efficacy of Meplazumab in
addition to Standard of Care for the treatment of Corona Virus Disease(COVID) 19 in
hospitalized adults
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd